Shopping Cart

Your shopping cart is currently empty

SRI-29329

Name: SRI-29329
Brand: TargetMol
SKU: T8801
Price: 84 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T8801Cas No. 2086809-58-5

SRI-29329 is a potent, specific inhibitor of CDC-like kinase (with IC50 of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively).

SRI-29329

Copy Product Info

🥰Excellent

Purity: 99.18%

Catalog No. T8801Cas No. 2086809-58-5

SRI-29329 is a potent, specific inhibitor of CDC-like kinase (with IC50 of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively).

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$84	In Stock	In Stock
5 mg	$198	In Stock	In Stock
10 mg	$323	In Stock	In Stock
25 mg	$547	In Stock	In Stock
50 mg	$788	In Stock	In Stock
100 mg	$1,080	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$226	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.18%

Appearance:Solid

Color:Yellow

Resource Download

COA LCMS HNMR

Product Introduction

SRI-29329 AI Summary

SRI-29329 exhibits bioactivity as a potent inhibitor of several kinases, particularly CLK2 with an IC50 of 16.0 nM, CLK1 with an IC50 of 78.0 nM, and human CLK4 with an IC50 of 86.0 nM. It demonstrates selectivity towards CLK1 over CLK2 with a selectivity ratio of 5.0. Additionally, the compound exhibits moderate inhibitory activity against MEKK2, Plk1, and Src kinases and inhibits CLK-mediated SF3B1 activation in human SK-MEL-2 cells with an EC50 of 11700.0 nM. SRI-29329 has varying effects on cell viability; in HEK293T cells, it shows a tendency to decrease cell growth rates, while in U2OS cells and human fibroblasts, the effects are mixed. Thermal Shift Assays reveal that SRI-29329 affects the melting temperature (TM) of different protein domains variably, either stabilizing or destabilizing them. This suggests that the compound interacts differently with various protein regions, potentially impacting their stability and function..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	SRI-29329 is a potent, specific inhibitor of CDC-like kinase (with IC50 of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively).
Targets&IC50	CLK1:78 nM , CLK2:16 nM , CLK4:86 nM

Chemical Properties

Molecular Weight	399.92
Formula	C₂₀H₂₆ClN₇
Cas No.	2086809-58-5
Smiles	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(N[C@H]3CCCC[C@@H]3N)nc12
Relative Density.	no data available

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 32.5 mg/mL (81.27 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.5005 mL	12.5025 mL	25.0050 mL	125.0250 mL
5 mM	0.5001 mL	2.5005 mL	5.0010 mL	25.0050 mL
10 mM	0.2501 mL	1.2503 mL	2.5005 mL	12.5025 mL
20 mM	0.1250 mL	0.6251 mL	1.2503 mL	6.2513 mL
50 mM	0.0500 mL	0.2501 mL	0.5001 mL	2.5005 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc